Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SafiledCriticalGlenmark Pharmaceuticals Sa
Priority to TNP2011000521ApriorityCriticalpatent/TN2011000521A1/en
Publication of TN2011000521A1publicationCriticalpatent/TN2011000521A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
the present invention related to fused pyrimidine derivatives which are useful as transient receptor potential vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein.
TNP2011000521A2011-10-142011-10-14Fused pyrimidine derivatives as trpv3 modulators
TN2011000521A1
(en)